Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population
- 152 Downloads
Hospice provides integrative palliative care for advance-staged hepatocellular carcinoma (HCC) patients, but hospice utilization in HCC patients in the USA is not clearly understood.
We examined hospice use and subsequent clinical course in advance-staged HCC patients.
We conducted a retrospective study on a national, Veterans Affairs cohort with stage C or D HCC. We evaluated demographics, clinical factors, treatment, and clinical course in relation to hospice use.
We identified 814 patients with advanced HCC, of whom 597 (73.3%) used hospice. Oncologist management consistently predicted hospice use, irrespective of HCC treatment [no treatment: OR 2.25 (1.18–4.3), treatment: OR 1.80 (1.10–2.95)]. Among patients who received HCC treatment, hospice users were less likely to have insurance beyond VA benefits (47.2 vs. 60.0%, p = 0.01). Among patients without HCC treatment, hospice users were older (62.2 [17.2] vs. 60.2 [14.0] years, p = 0.05), white (62.1 vs. 52.9%, p = 0.01), resided in the Southern USA (39.5 vs. 31.8%, p = 0.05), and had a performance score ≥ 3 (41.9 vs. 31.8%, p = 0.01). The median time from hospice entry to death or end of study was 1.05 [2.96] months for stage C and 0.53 [1.18] months for stage D patients.
26.7% advance-staged HCC patients never entered hospice, representing potential missed opportunities for improving end-of-life care. Age, race, location, performance, insurance, and managing specialty can predict hospice use. Differences in managing specialty and short-term hospice use suggest that interventions to optimize early palliative care are necessary.
KeywordsHospice Palliative care Hepatocellular carcinoma Veteran
This project was supported in part by the National Cancer Institute (R01 CA160738; PI, J. Davila), and the facilities and resources Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.
WYZ designed the study, acquired, analyzed, and interpreted the data and drafted the manuscript. HBE and JAD conceptualized and designed the study and critically revised the manuscript. YHS, SLT, and SS acquired, analyzed, and interpreted the data. FK analyzed and interpreted the data and provided critical revision for the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 2.Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2015;385:117–171. https://doi.org/10.1016/s0140-6736(14)61682-2.CrossRefGoogle Scholar
- 8.Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol. 2014;12:692–698. https://doi.org/10.1016/j.cgh.2013.08.027.CrossRefPubMedGoogle Scholar
- 9.Kelly SG, Campbell TC, Hillman L, Said A, Lucey MR, Agarwal PD. The utilization of palliative care services in patients with cirrhosis who have been denied liver transplantation: a single center retrospective review. Ann Hepatol. 2017;16:395–401. https://doi.org/10.5604/16652681.1235482.CrossRefPubMedGoogle Scholar
- 16.Spencer KL, Mrig EH, Matlock DD, Kessler ER. A qualitative investigation of cross-domain influences on medical decision making and the importance of social context for understanding barriers to hospice use. J Appl Soc Sci. 2017;11:48–59. https://doi.org/10.1177/1936724417692377.CrossRefGoogle Scholar